Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ).
CARsgen Therapeutics Holdings Ltd. announced the composition of its board of directors and their respective roles within the company. The board includes executive, non-executive, and independent non-executive directors, with specific members assigned to the audit, remuneration, and nomination and corporate governance committees. This announcement provides clarity on the governance structure of the company, which is crucial for stakeholders as it can impact decision-making processes and strategic direction.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$14.92 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd. is a biotechnology company incorporated in the Cayman Islands, focusing on innovative therapies in the healthcare industry. The company is involved in the development of CAR-T cell therapies for the treatment of cancer, aiming to address unmet medical needs in this field.
Average Trading Volume: 2,607,231
Technical Sentiment Signal: Hold
Current Market Cap: HK$11.68B
See more data about 2171 stock on TipRanks’ Stock Analysis page.